Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$33.54 - $55.0 $38.6 Million - $63.4 Million
-1,152,341 Reduced 57.36%
856,658 $47.1 Million
Q1 2022

May 16, 2022

SELL
$31.02 - $48.18 $14.9 Million - $23.1 Million
-480,004 Reduced 19.28%
2,008,999 $73 Million
Q4 2021

Feb 14, 2022

BUY
$41.14 - $56.98 $5.14 Million - $7.12 Million
125,000 Added 5.29%
2,489,003 $116 Million
Q3 2021

Nov 15, 2021

BUY
$35.31 - $50.56 $24.7 Million - $35.4 Million
699,469 Added 42.02%
2,364,003 $120 Million
Q2 2021

Aug 16, 2021

BUY
$25.8 - $41.09 $40 Million - $63.6 Million
1,548,908 Added 1339.58%
1,664,534 $68.3 Million
Q4 2020

Feb 16, 2021

SELL
$25.8 - $32.39 $324,409 - $407,271
-12,574 Reduced 9.81%
115,626 $3.26 Million
Q3 2020

Nov 16, 2020

SELL
$27.5 - $39.61 $187,000 - $269,348
-6,800 Reduced 5.04%
128,200 $3.96 Million
Q2 2020

Aug 14, 2020

BUY
$36.1 - $42.56 $4.87 Million - $5.75 Million
135,000 New
135,000 $5.75 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $5.49B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.